BridgeBio Pharma BBIO License — Revenue
Discontinued — last reported Q4 '24
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BridgeBio Pharma’s 10-K, filed February 20, 2025, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's license — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's license — revenue?
- BridgeBio Pharma (BBIO) reported license — revenue of $300K in Q4 2024.
- How has BridgeBio Pharma's license — revenue changed year-over-year?
- BridgeBio Pharma's license — revenue decreased by 0.0% year-over-year, from $300K to $300K.
- What is the long-term trend for BridgeBio Pharma's license — revenue?
- Over 3 years (2021 to 2024), BridgeBio Pharma's license — revenue has grown at a 32.6% compound annual growth rate (CAGR), from $56.46M to $131.5M.
- What does license — revenue mean?
- The total revenue earned from licensing agreements and collaborations, excluding taxes.
- How do you interpret license — revenue?
- An increase indicates successful commercialization or milestone achievement within the licensing segment, while a decrease suggests lower partnership activity or fewer milestone triggers.
- How does license — revenue compare across companies?
- Standard revenue line item for biopharma companies with licensing-heavy business models, comparable to 'Licensing Revenue' or 'Collaboration Revenue'.